Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties ; volume:13 ; number:1 ; day:15 ; month:11 ; year:2018 ; pages:1-15 ; date:12.2018
Orphanet journal of rare diseases ; 13, Heft 1 (15.11.2018), 1-15, 12.2018
- Creator
-
Pontes, Caridad
Fontanet, Juan Manuel
Vives, Roser
Sancho, Aranzazu
Gómez-Valent, Mònica
Ríos, José
Morros, Rosa
Martinalbo, Jorge
Posch, Martin
Koch, Armin
Roes, Kit
Rengerink, Katrien Oude
Torrent-Farnell, Josep
Torres, Ferran
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-018-0926-z
- URN
-
urn:nbn:de:101:1-2018121519305594341506
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pontes, Caridad
- Fontanet, Juan Manuel
- Vives, Roser
- Sancho, Aranzazu
- Gómez-Valent, Mònica
- Ríos, José
- Morros, Rosa
- Martinalbo, Jorge
- Posch, Martin
- Koch, Armin
- Roes, Kit
- Rengerink, Katrien Oude
- Torrent-Farnell, Josep
- Torres, Ferran
- SpringerLink (Online service)
Other Objects (12)
Comparing access to orphan medicinal products in Europe
The European challenges of funding orphan medicinal products
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Implication of methodological uncertainties for mid-Holocene sea surface temperature reconstructions
The Orphan
Orphan Island
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
Comparing access to orphan medicinal products in Europe
The European challenges of funding orphan medicinal products
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Implication of methodological uncertainties for mid-Holocene sea surface temperature reconstructions
The Orphan
Orphan Island
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
Comparing access to orphan medicinal products in Europe
The European challenges of funding orphan medicinal products
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Implication of methodological uncertainties for mid-Holocene sea surface temperature reconstructions
The Orphan
Orphan Island
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?